Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD8-α CRISPR/Cas9 KO Plasmid (h): sc-400372
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD8-α CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CD8-α genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD8-α Antibody (D-9): sc-7970
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD8-α CRISPR/Cas9 KO Plasmid (h) | sc-400372 | 20 µg | $397.00 |
Overview
CD8A encodes CD8-α, a type I membrane glycoprotein that forms CD8αα homodimers or CD8αβ heterodimers on T cells and a subset of NK cells, acting as a co-receptor for MHC class I–restricted antigen recognition. By binding MHC I and associating with LCK, CD8-α promotes TCR signaling, immunological synapse formation, and downstream pathways controlling cytotoxic effector differentiation and cytokine production. CD8A expression is widely used to define cytotoxic lymphocyte states and to dissect lineage specification, activation, and exhaustion programs. Dysregulation of CD8-α–dependent signaling and CD8+ T-cell phenotypes is relevant to tumor immune microenvironments, chronic viral infection, autoimmunity, and immune deficiency research contexts.
CD8-α CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CD8A gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CD8A together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CD8A open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CD8-α protein expression.
This CRISPR knockout system enables efficient generation of CD8A-deficient cell models for investigation of CD8-α signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CD8A exon(s) critical for CD8-α function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CD8A genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CD8-α CRISPR/Cas9 KO Plasmid (h) and CD8-α CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CD8A locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CD8-α HDR Plasmid (h) and CD8-α HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CD8A homology arms to support homology-directed repair at defined CD8A target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.